Experimental research on the development of new treatment strategies for triple negative breast cancer

我们使用乳腺癌细胞系进行了实验研究，以研究聚ADP-核糖聚合酶（PARP）1抑制剂奥拉帕尼和mTOR抑制剂依维莫司（EVE）的抗肿瘤活性。我们还研究了药物对CSC比例的影响。奥拉帕尼不仅在TNBC细胞系中，而且在ER阳性、HER 2阴性细胞系中具有生长抑制活性。奥拉帕尼与抗雌激素（AE）的联合治疗在ER阳性细胞系中产生了累加的生长抑制作用。使用一组不同亚型的人乳腺癌细胞系研究EVE的抗肿瘤活性。EVE对BRCA 1突变的TNBC细胞株具有强烈的生长抑制作用，对部分ER阳性乳腺癌细胞株也表现出中度的生长抑制作用。EVE有降低大多数细胞系CSC比例的趋势。

We conducted experimental studies to investigate anti-tumor activity of a poly-ADP-ribose polymerase (PARP) 1 inhibitor olaparib and a mTOR inhibitor everolimus (EVE) using breast cancer cell lines. We also investigated the effects of the agents on the ratio of CSC. Olaparib possesses growth inhibitory activity in not only TNBC cell lines but also ER-positive, HER2-negative cell lines. A combined treatment of olaparib with antiestrogen (AE) rendered an additive growth inhibitory effect in ER-positive cell lines. Anti-tumor activity of EVE was investigated using a panel of human breast cancer cell lines of various subtypes. EVE possessed a drastic growth inhibitory effect on a BRCA1-mutated, TNBC cell line and also exhibited a moderate growth inhibitory effect on a part of ER-positive breast cancer cells lines. EVE tended to decrease the ratio of CSC in most cell lines.